e-learning
resources
Berlin 2001
Monday 24.09.2001
Problems in treatment of TB
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy
G. Cicchitto, A. Vaghi, N. Grassi, S. Capato, G. Besozzi, S. De Lorenzo, G. B. Migliori, R. Centis (Garbagnate, Sondalo, Tradate, Italy)
Source:
Annual Congress 2001 - Problems in treatment of TB
Session:
Problems in treatment of TB
Session type:
Thematic Poster Session
Number:
2076
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Cicchitto, A. Vaghi, N. Grassi, S. Capato, G. Besozzi, S. De Lorenzo, G. B. Migliori, R. Centis (Garbagnate, Sondalo, Tradate, Italy). Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy. Eur Respir J 2001; 16: Suppl. 31, 2076
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005
Predictors of treatment outcome in multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Source: Eur Respir J 2013; 42: 1747-1749
Year: 2013
Evaluation of treatment outcomes for multidrug-resistant tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001
Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study
Source: Eur Respir J 2006; 28: 980-985
Year: 2006
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Long-term results of multidrug-resistant tuberculosis treatment.
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
Source: Eur Respir J 2015; 45: 1498-1501
Year: 2015
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB)
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis
Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Year: 2020
When do we extend the treatment of tuberculosis (TB) more than 6 months?
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
Multidrug-resistant tuberculosis in UK children: presentation, management and outcome
Source: Eur Respir J 2013; 41: 1456-1458
Year: 2013
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013
Reducing loss to follow-up during treatment for drug-resistant tuberculosis
Source: Eur Respir J, 53 (1) 1802268; 10.1183/13993003.02268-2018
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept